<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04136366</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-2191-PVR-001</org_study_id>
    <nct_id>NCT04136366</nct_id>
  </id_info>
  <brief_title>The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy</brief_title>
  <official_title>The GUARD Trial - Part 1: A Phase 3 Clinical Trial of Repeated Intravitreal Injections of ADX-2191 Versus Standard-of-Care for Prevention of Proliferaivie Vitreoretinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The GUARD Trial is a multi-center, randomized, controlled, adaptive Phase 3 clinical trial of&#xD;
      repeated intravitreal injections of ADX-2191 versus standard-of-care for the prevention of&#xD;
      proliferative vitreoretinopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 15, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent retinal detachment</measure>
    <time_frame>Efficacy assessment period (Week 1 to Week 24)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best-corrected visual acuity (BCVA) change from baseline</measure>
    <time_frame>Efficacy assessment period (Week 1 to Week 24)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Proliferative Vitreoretinopathy</condition>
  <arm_group>
    <arm_group_label>ADX-2191 (intravitreal methotrexate 0.8%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ADX-2191 (intravitreal methotrexate 0.8%) administered over 16 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard surgical care procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard procedure performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-2191 (intravitreal methotrexate 0.8%)</intervention_name>
    <description>ADX-2191 (intravitreal methotrexate 0.8%) injected 13 times over 16 weeks upon completion of pars plana vitrectomy</description>
    <arm_group_label>ADX-2191 (intravitreal methotrexate 0.8%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard surgical care procedure</intervention_name>
    <description>Standard surgical care performed upon completion of pars plana vitrectomy</description>
    <arm_group_label>Standard surgical care procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is 18 years or older of any gender or race&#xD;
&#xD;
          2. Subject is undergoing pars plana vitrectomy due to recurrent retinal detachment due to&#xD;
             proliferative vitreoretionapthy or open globe injury&#xD;
&#xD;
          3. Subject is willing and able to provide written informed consent, comply with clinical&#xD;
             trial procedures, and return for all clinical trial visits&#xD;
&#xD;
          4. Subjects of childbearing potential must agree to use two forms of birth control for&#xD;
             the duration of the clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of severe non-proliferative or proliferative diabetic retinopathy&#xD;
&#xD;
          2. Other planned eye surgery during the course of the trial&#xD;
&#xD;
          3. Participation in a clinical trial with an investigational medicinal product or&#xD;
             investigational device within 90 days of subject enrollment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bill Cavanagh</last_name>
    <phone>781-257-3063</phone>
    <email>bcavanagh@aldeyra.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Derek Y. Kunimoto, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara McCannel, MD</last_name>
      <phone>310-206-7484</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Retina Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S.K. Steven Houston III, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Palm Beach Gardens</city>
        <state>Florida</state>
        <zip>33418</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jorge Fortun, MD</last_name>
      <phone>305-243-5757</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G. Baker Hubbard III, MD</last_name>
      <phone>404-778-4182</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Lim, MD</last_name>
      <phone>312-996-6660</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Pollack, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen M. Gehrs, MD</last_name>
      <phone>319-356-1616</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Liang, MD</last_name>
      <phone>617-636-5000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey S. Heier, MD</last_name>
      <phone>800-635-0489</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leo Kim, MD</last_name>
      <phone>617-573-5896</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>New England Retina Consultants</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lally, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kresge Eye Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xihui Lin, MD</last_name>
      <phone>313-577-8900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associated Retinal Consultants</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamer Mahmoud, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Surgery</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Mittra, MD</last_name>
      <phone>952-929-1311</phone>
    </contact>
    <contact_backup>
      <last_name>Neal Oestreich</last_name>
      <phone>952-259-6262</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Ophthalmology</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Lezzi Jr., MD</last_name>
      <phone>507-284-2744</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin Blinder, MD</last_name>
      <phone>314-367-1181</phone>
    </contact>
    <contact_backup>
      <last_name>Pam Bilyeu</last_name>
      <phone>314-367-1181</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Long Island VitreoRetinal Consultants</name>
      <address>
        <city>Forest Hills</city>
        <state>New York</state>
        <zip>11375</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan M. Romero, MD</last_name>
      <phone>718-793-6430</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke Health Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lejla Vajzovic, MD</last_name>
      <phone>919-681-3937</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>OHSU Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina J. Flaxel, MD</last_name>
      <phone>503-494-3000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason Hsu, MD</last_name>
      <phone>800-331-6634</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Wykoff, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yewlin Chee, MD</last_name>
      <phone>206-744-2020</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 21, 2019</study_first_submitted>
  <study_first_submitted_qc>October 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2019</study_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ADX-2191</keyword>
  <keyword>recurrent retinal detachment</keyword>
  <keyword>open globe injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitreoretinopathy, Proliferative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

